| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: IMRX |
| Security Type |
Common Stock |
| Lead Underwriter |
CIBC World Markets Inc |
| Days In Registration |
200 |
| Date Filed |
19-May-2006 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Manufacture, develop and market thrombolytic drugs and therapies for vascular disorders with products such as Abbokinase and Sonolysis that both aim to break up blood clots and restore blood flow to oxygen deprived tissues |
| Revenue |
$1.3M |
| Net Income |
-$0.7M |
| Shares Outstanding (post-offering) |
17.72M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
5.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
750.0K |
| File Amount |
- |
| File Price Range |
$12.00 - $10.00 |
| File Mid Price |
$11.00 |
|
